These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11006766)

  • 21. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colorectal cancer screening.
    Ederer F; Church T; Mandel J
    Scand J Gastroenterol; 2004 Oct; 39(10):1031-2; author reply 1029-30. PubMed ID: 15513349
    [No Abstract]   [Full Text] [Related]  

  • 23. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Colorectal cancer screening: advice from the Health Council of the Netherlands].
    van Veen W; Mali WP
    Ned Tijdschr Geneeskd; 2009; 153():A1441. PubMed ID: 20003552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.
    Solomon MJ; McLeod RS
    CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.
    UK Colorectal Cancer Screening Pilot Group
    BMJ; 2004 Jul; 329(7458):133. PubMed ID: 15237087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychological distress following fecal occult blood test in colorectal cancer screening--a population-based study.
    Brasso K; Ladelund S; Frederiksen BL; Jørgensen T
    Scand J Gastroenterol; 2010 Oct; 45(10):1211-6. PubMed ID: 20443744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
    Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which colorectal cancer screening test is best?
    Mandel JS
    J Natl Cancer Inst; 2007 Oct; 99(19):1424-5. PubMed ID: 17895471
    [No Abstract]   [Full Text] [Related]  

  • 30. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs.
    El-Serag HB; Petersen L; Hampel H; Richardson P; Cooper G
    Arch Intern Med; 2006 Nov; 166(20):2202-8. PubMed ID: 17101937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing risks and benefits of colorectal cancer screening in elderly patients.
    Ko CW; Sonnenberg A
    Gastroenterology; 2005 Oct; 129(4):1163-70. PubMed ID: 16230070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in performance of fecal occult blood testing.
    Brenner H; Haug U; Hundt S
    Am J Gastroenterol; 2010 Nov; 105(11):2457-64. PubMed ID: 20700114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A system-based intervention to improve colorectal cancer screening uptake.
    Hoffman RM; Steel SR; Yee EF; Massie L; Schrader RM; Moffett ML; Murata GH
    Am J Manag Care; 2011 Jan; 17(1):49-55. PubMed ID: 21348568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
    Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
    Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel molecular screening approaches in colorectal cancer.
    Miller S; Steele S
    J Surg Oncol; 2012 Apr; 105(5):459-67. PubMed ID: 22441897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.